Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00158873 |
The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.
Condition | Intervention | Phase |
---|---|---|
Sedation |
Drug: midazolam Drug: lorazepam Drug: fentanyl Drug: morphine Drug: remifentanil Drug: propofol |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Efficacy Study |
Official Title: | A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation |
Estimated Enrollment: | 224 |
Study Start Date: | September 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Netherlands | |
GSK Investigational Site | |
ALKMAAR, Netherlands, 1815 JD | |
GSK Investigational Site | |
DEN HAAG, Netherlands, 2512 VA | |
GSK Investigational Site | |
EINDHOVEN, Netherlands, 5623 EJ | |
GSK Investigational Site | |
DORDRECHT, Netherlands, 3318 AT | |
GSK Investigational Site | |
EDE, Netherlands, 6716 RP | |
GSK Investigational Site | |
HAARLEM, Netherlands, 2035 RC | |
GSK Investigational Site | |
APELDOORN, Netherlands, 7334 DZ | |
GSK Investigational Site | |
VENLO, Netherlands, 5912 BL | |
GSK Investigational Site | |
TIEL, Netherlands, 4002 WP | |
GSK Investigational Site | |
AMSTERDAM, Netherlands, 1081 HV | |
GSK Investigational Site | |
ZWOLLE, Netherlands, 8011 JW | |
GSK Investigational Site | |
HELMOND, Netherlands, 5707 HA | |
GSK Investigational Site | |
HENGELO, Netherlands, 7555 DL | |
GSK Investigational Site | |
DEN BOSCH, Netherlands, 5211 RW | |
GSK Investigational Site | |
ROTTERDAM, Netherlands, 3015 GJ |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 101653 |
Study First Received: | September 8, 2005 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00158873 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
ICU
mechanical ventilation
analgesia
sedation |
Lorazepam Morphine Fentanyl |
Remifentanil Propofol Midazolam |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Anesthetics Antiemetics Sensory System Agents Therapeutic Uses Hypnotics and Sedatives Analgesics Analgesics, Opioid Anesthetics, Intravenous |
Tranquilizing Agents Gastrointestinal Agents Central Nervous System Depressants Narcotics Pharmacologic Actions Adjuvants, Anesthesia Anesthetics, General Autonomic Agents GABA Agents Anti-Anxiety Agents Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants |